Literature DB >> 25589932

Synthesis and Biological Evaluation of Pyrazolo[1,5-a]pyrimidine Compounds as Potent and Selective Pim-1 Inhibitors.

Yong Xu1, Benjamin G Brenning1, Steven G Kultgen1, Jason M Foulks1, Adrianne Clifford1, Shuping Lai1, Ashley Chan1, Shannon Merx1, Michael V McCullar1, Steven B Kanner1, Koc-Kan Ho1.   

Abstract

Pim-1 has emerged as an attractive target for developing therapeutic agents for treating disorders involving abnormal cell growth, especially cancers. Herein we present lead optimization, chemical synthesis and biological evaluation of pyrazolo[1,5-a]pyrimidine compounds as potent and selective inhibitors of Pim-1 starting from a hit from virtual screening. These pyrazolo[1,5-a]pyrimidine compounds strongly inhibited Pim-1 and Flt-3 kinases. Selected compounds suppressed both the phosphorylation of BAD protein in a cell-based assay and 2-dimensional colony formation in a clonogenic cell survival assay at submicromolar potency, suggesting that cellular activity was mediated through inhibition of Pim-1. Moreover, these Pim-1 inhibitors did not show significant hERG inhibition at 30 μM concentration. The lead compound proved to be highly selective against a panel of 119 oncogenic kinases, indicating it had an improved safety profile compared with the first generation Pim-1 inhibitor SGI-1776.

Entities:  

Keywords:  2-dimensional colony formation; BAD phosphorylation; Pim-1 inhibitor; Pyrazolo[1,5-a]pyrimidine; hERG inhibition; kinase selectivity

Year:  2014        PMID: 25589932      PMCID: PMC4291737          DOI: 10.1021/ml500300c

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  24 in total

1.  Comprehensive analysis of kinase inhibitor selectivity.

Authors:  Mindy I Davis; Jeremy P Hunt; Sanna Herrgard; Pietro Ciceri; Lisa M Wodicka; Gabriel Pallares; Michael Hocker; Daniel K Treiber; Patrick P Zarrinkar
Journal:  Nat Biotechnol       Date:  2011-10-30       Impact factor: 54.908

2.  Synthesis of pyrazolo[1,5-alpha]pyrimidinone regioisomers.

Authors:  Lori K Gavrin; Arthur Lee; Brian A Provencher; Walter W Massefski; Stephen D Huhn; Gregory M Ciszewski; Derek C Cole; John C McKew
Journal:  J Org Chem       Date:  2007-02-02       Impact factor: 4.354

3.  Comparison of in vitro methods to determine drug-induced cell lethality.

Authors:  P R Roper; B Drewinko
Journal:  Cancer Res       Date:  1976-07       Impact factor: 12.701

4.  Measuring and interpreting the selectivity of protein kinase inhibitors.

Authors:  Lynette A Smyth; Ian Collins
Journal:  J Chem Biol       Date:  2009-06-06

5.  Overexpression of PIM-1 is a potential biomarker in prostate carcinoma.

Authors:  Yong Xu; Tong Zhang; Hua Tang; Shumin Zhang; Min Liu; Dalin Ren; Yuanjie Niu
Journal:  J Surg Oncol       Date:  2005-12-15       Impact factor: 3.454

6.  PIM-1 gene RNA interference induces growth inhibition and apoptosis of prostate cancer cells and suppresses tumor progression in vivo.

Authors:  Tong Zhang; Xiaoguang Zhang; Kejia Ding; Kuo Yang; Zhihong Zhang; Yong Xu
Journal:  J Surg Oncol       Date:  2010-05-01       Impact factor: 3.454

7.  Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells.

Authors:  Lisa S Chen; Sanjeev Redkar; David Bearss; William G Wierda; Varsha Gandhi
Journal:  Blood       Date:  2009-09-04       Impact factor: 22.113

8.  The human protooncogene product p33pim is expressed during fetal hematopoiesis and in diverse leukemias.

Authors:  R Amson; F Sigaux; S Przedborski; G Flandrin; D Givol; A Telerman
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

9.  Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study.

Authors:  Eric D Hsi; Sin-Ho Jung; Raymond Lai; Jeffrey L Johnson; James R Cook; Dan Jones; Sven Devos; Bruce D Cheson; Lloyd E Damon; Jonathan Said
Journal:  Leuk Lymphoma       Date:  2008-11

10.  A small-molecule inhibitor of PIM kinases as a potential treatment for urothelial carcinomas.

Authors:  Jason M Foulks; Kent J Carpenter; Bai Luo; Yong Xu; Anna Senina; Rebecca Nix; Ashley Chan; Adrianne Clifford; Marcus Wilkes; David Vollmer; Benjamin Brenning; Shannon Merx; Shuping Lai; Michael V McCullar; Koc-Kan Ho; Daniel J Albertson; Lee T Call; Jared J Bearss; Sheryl Tripp; Ting Liu; Bret J Stephens; Alexis Mollard; Steven L Warner; David J Bearss; Steven B Kanner
Journal:  Neoplasia       Date:  2014-06-18       Impact factor: 5.715

View more
  5 in total

1.  A novel protocol for catalyst-free synthesis of fused six-member rings to triazole and pyrazole.

Authors:  Sedigheh Akrami; Bahador Karami; Mahnaz Farahi
Journal:  Mol Divers       Date:  2019-04-01       Impact factor: 2.943

2.  Predictive Model for Site-Selective Aryl and Heteroaryl C-H Functionalization via Organic Photoredox Catalysis.

Authors:  Kaila A Margrey; Joshua B McManus; Simone Bonazzi; Frederic Zecri; David A Nicewicz
Journal:  J Am Chem Soc       Date:  2017-08-07       Impact factor: 15.419

3.  Efficient Access to 3,5-Disubstituted 7-(Trifluoromethyl)pyrazolo[1,5-a]pyrimidines Involving SNAr and Suzuki Cross-Coupling Reactions.

Authors:  Badr Jismy; Abdellatif Tikad; Mohamed Akssira; Gérald Guillaumet; Mohamed Abarbri
Journal:  Molecules       Date:  2020-04-28       Impact factor: 4.411

4.  Targeting Echinococcus multilocularis PIM kinase for improving anti-parasitic chemotherapy.

Authors:  Akito Koike; Frank Becker; Peter Sennhenn; Jason Kim; Jenny Zhang; Stefan Hannus; Klaus Brehm
Journal:  PLoS Negl Trop Dis       Date:  2022-10-03

Review 5.  Functional Pyrazolo[1,5-a]pyrimidines: Current Approaches in Synthetic Transformations and Uses As an Antitumor Scaffold.

Authors:  Andres Arias-Gómez; Andrés Godoy; Jaime Portilla
Journal:  Molecules       Date:  2021-05-05       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.